Physician profile
Frank Barnes
NPI 1003872144
$6,245.26
in general payments reported to CMS, 2019-2025
25 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $288 · 2021: $444 · 2022: $1,082 · 2023: $554 · 2024: $1,972 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,665.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,034.04 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $637.57 | 2022-2025 | Tyrvaya |
| Alcon Vision LLC | $637.22 | 2019-2025 | Tryptyr, Total30, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $579.15 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $491.62 | 2019-2025 | Cequa |
| Sight Sciences, INC. | $468.27 | 2020-2024 | Omni Surgical System |
| Allergan, INC. | $387.47 | 2019-2022 | |
| Abbvie INC. | $368.24 | 2022-2025 | Lumigan, Durysta, Alphagan P |
| Visioneering Technologies, INC. | $264.77 | 2019-2025 | |
| Harrow Eye, LLC | $249.60 | 2024-2025 | Vevye |
| Glaukos Corporation | $191.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $139.10 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $133.06 | 2019-2023 | Tobradex St |
| Lkc Technologies, INC. | $95.77 | 2024 | |
| Kala Pharmaceuticals, INC. | $81.75 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $76.41 | 2023-2024 | Oxervate |
| Biotissue Holdings INC. | $74.66 | 2024 | |
| Aerie Pharmaceuticals, INC. | $68.75 | 2019-2021 | |
| Coopervision INC. | $65.12 | 2023-2024 | Myday Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $53.69 | 2021-2025 | |
| Samsara Vision | $50.00 | 2022 | |
| Shire North American Group INC | $46.89 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.